FARALLON CAPITAL MANAGEMENT LLC
Q3 2020 13F-HR Holdings
Net value change ($000)
+1,918,870
(15.7%)
New positions
30
Sold out positions
24
Turnover %
22.1%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q2 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IMMUNOMEDICS INC | 498,276 | NEW |
| BSX | 316,223 | NEW |
| GOOGL | 220,442 | 70.5% |
| Wright Medical Group N.V. | 155,679 | NEW |
| HLT | 131,894 | NEW |
| NYT | 130,167 | 74.9% |
| NEW ORIENTAL EDUCATION | 122,457 | 149.0% |
| Livongo Health, Inc. | 116,242 | NEW |
| HWM | 101,551 | 534.3% |
| TMO | 96,196 | 24.8% |
Top Reduces (Value $000, Stocks/ETFs)
| MTCH | -455,994 | -100.0% |
| 58.com Inc. | -267,824 | -100.0% |
| QGEN | -123,336 | -100.0% |
| CRM | -110,299 | -38.6% |
| CAESARS HOLDINGS, INC. | -97,222 | -100.0% |
| UTHR | -42,350 | -100.0% |
| EQIX | -35,782 | -19.0% |
| ABBV | -35,189 | -8.6% |
| CNC | -33,623 | -7.6% |
| PORTOLA PHARMACEUTICALS INC | -33,187 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
343,942
(2.4% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|